Key Takeaways
- ImmunityBio received an FDA warning letter concerning a television advertisement and podcast episode that contained misleading statements about ANKTIVA, its bladder cancer treatment
- The marketing content falsely implied ANKTIVA works against all cancer types — the drug is exclusively approved for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
- Both CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong were specifically identified in the regulatory violation notice
- ImmunityBio has now received three separate FDA communications regarding promotional violations, with previous notices sent in September 2025 and January 2026
- ImmunityBio must submit a comprehensive corrective action plan within 15 working days or potentially face legal proceedings
Shares of ImmunityBio experienced a significant decline on Tuesday following regulatory scrutiny from the FDA, which identified violations in a television commercial and podcast episode that made unsubstantiated claims regarding the approved therapeutic applications of ANKTIVA. This represents the third instance of the company encountering regulatory challenges related to its marketing practices.
The FDA’s Office of Prescription Drug Promotion delivered a formal warning letter to ImmunityBio in response to a television advertisement and a podcast episode entitled “Is the FDA BLOCKING Life Saving Cancer Treatments?” Regulators concluded that both promotional pieces breached federal regulations.
The fundamental problem centered on the scope of claims. ANKTIVA has received approval for a narrow therapeutic application: the treatment of adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer featuring carcinoma in situ, either with or without papillary tumors, delivered through direct bladder administration in combination with BCG therapy.
The marketing campaigns dramatically exceeded these boundaries. The materials indicated that ANKTIVA could “treat all cancers,” offer cancer prevention for individuals with radiation exposure, and function as a standalone single-injection therapy. Not one of these assertions has clinical evidence backing it or FDA authorization.
Both CEO Richard Adcock and Executive Chairman Dr. Patrick Soon-Shiong featured prominently in these materials and were individually named in the regulatory correspondence.
According to the FDA, the promotional content misbranded ANKTIVA and rendered the drug’s commercial distribution a violation of the Federal Food, Drug, and Cosmetic Act.
Repeat Offender Status
This regulatory action represents far from the initial instance where ImmunityBio has faced scrutiny for promotional misconduct. The FDA previously dispatched untitled letters during September 2025 and January 2026 to Altor BioScience, an ImmunityBio subsidiary, addressing comparable promotional infractions.
Tuesday’s correspondence represents the third such regulatory action — and carries the greatest severity. An FDA warning letter possesses substantially more regulatory authority than an untitled letter and demonstrates the agency’s growing apprehension.
The FDA additionally cited ImmunityBio for inadequately presenting risk information within the marketing materials and for excluding critical details regarding the drug’s authorized indication.
The podcast episode also was not filed with the FDA when it was originally released, representing an additional regulatory requirement the company neglected to fulfill.
Investor Response
IBRX stock declined approximately 15% to 21% throughout Tuesday’s trading session, with certain reports indicating the selloff reached depths of 21% during early market hours.
ImmunityBio must now deliver a written response to the FDA within 15 working days detailing a comprehensive remediation strategy to address the violations.
The biotechnology company faces an additional requirement to deploy corrective communications specifically directed toward individuals who were exposed to the misleading promotional content.
The FDA cautioned that inadequate corrective measures could trigger legal enforcement actions.
